T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4136-4144

  Wahlin, Björn Engelbrekt ^a   Sundström, Christer ^d   Holte, Harald ^e   Hagberg, Hans ^d   Erlanson, Martin ^g   Nilsson Ehle, Herman ^h   Lindén, Ola ⁱ   Nordström, Marie ^b   Østenstad, Bjørn ^f   Geisler, Christian H ^j   Brown, Peter De Nully ^j   Lehtinen, Tuula ^k   Maisenhölder, Martin ^l   Tierens, Anne M ^e   Sander, Birgitta ^c   Christensson, Birger ^c   Kimby, Eva ^a  

^a Department of Medicine   (Sweden)

^b Division of Hematology   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Oslo University Hospital ^*  (Norway)

^g UMEÅ UNIVERSITY   (Sweden)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j Rigshospitalet   (Denmark)

^k TAMPERE UNIVERSITY HOSPITAL   (Finland)

^l UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RITUXIMAB;

ADULT; ARTICLE; BLOOD LEVEL; CANCER TISSUE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 79959237067     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0264     Document Type: Article

References (37)

1. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69. (Pubitemid 39507628)
2. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
3. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64.
4. + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-9.
5. Alvaro T, Lejeune M, Salvadó MT, Lopez C, Jaén J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-7. (Pubitemid 46623165)
6. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388-97. (Pubitemid 46225341)
7. Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010;16:637-50.
8. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-8. (Pubitemid 350002987)
9. Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce LP, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008;111:4764-70.
10. Taskinen M, Karjalainen-Lindsberg ML, Leppa S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008;111:4664-7.
11. Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009;27:1470-6.
12. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010;115:289-95.
13. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-Doxorubicin- vincristine-prednisone. Clin Cancer Res 2007;13:5784-9. (Pubitemid 47591642)
14. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-6. (Pubitemid 351171697)
15. de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94:70-7.
16. Feuerlein K, Zucca E, Ghielmini M. First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma 2009;50:325-34.
17. Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:4480-4.
18. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42. (Pubitemid 39434941)
19. Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008;49:102-12. (Pubitemid 351146889)
20. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. (Pubitemid 39166497)
21. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
22. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675-82. (Pubitemid 41510143)
23. Czuczman MS, Grillo-Lopez AJ, Alkuzweny B, Weaver R, Larocca A, McLaughlin P. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma 2006;47:1830-40. (Pubitemid 44649768)
24. + T cells can be distinguished by their cytokine profiles and phenotypic markers. J Immunol 2000;164:208-16.
25. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 2009;113:3809-12.
26. Goold HD, Escors D, Conlan TJ, Chakraverty R, Bennett CL. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors. J Immunol 2011;186:4565-72.
27. Khanolkar A, Badovinac VP, Harty JT. CD8 T cell memory development: CD4 T cell help is appreciated. Immunol Res 2007;39:94-104.
28. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002;71:565-81.
29. Dondi E, Rogge L, Lutfalla G, Uze G, Pellegrini S. Down-modulation of responses to type I IFN upon T cell activation. J Immunol 2003;170:749-56. (Pubitemid 36070525)
30. Pangault C, Amé-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 2010;24:2080-9.
31. + T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4. J Immunol 2005;174:2021-9.
32. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010;95:2157-60.
33. + macrophages within the immediate sprouting microenvironment. Blood 2010;115:5053-6.
34. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
35. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639-46.
36. Bofill M, Janossy G, Lee CA, MacDonald-Burns D, Phillips AN, Sabin C, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol 1992;88:243-52.
37. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009;114:4713-20.